Introduction
Angiogenesis occurs physiologically during reproduction, embryonic development and wound repair. Furthermore, it also contributes to several pathological processes, including arthritis, atherosclerosis, diabetes and cancer (Carmeliet and Jain, 2000; Folkman, 2007) . VEGF-A (vascular endothelial growth factor) is the most angiogenic of the vascular growth factors. In tumours, VEGF-A is upregulated by hypoxia (Shweiki et al., 1992) or by the overexpression of oncogenes (Rak et al., 1995) , and it stimulates the proliferation and migration of endothelial cells, the sprouting of blood vessels and the generation of new vessels, resulting in sustained blood flow, oxygen supply and waste removal from the growing tumours (Ferrara et al., 2003) . In addition, VEGF-A regulates the function and physiology of some cancer cells themselves, by acting as an autocrine survival factor (Bachelder et al., 2001 (Bachelder et al., , 2002 . The importance of VEGF-A in cancer is attested by the use of anti-VEGF antibodies that have shown clinical benefits in colorectal, renal, breast and lung cancer (Hurwitz et al., 2004 (Hurwitz et al., , 2005 .
VEGF-A exists as multiple isoforms, which are generically referred to as VEGF xxx and result from the pre-mRNA alternative splicing of eight exons (Robinson and Stringer, 2001) . Alternative splicing of VEGF-A was initially shown to generate four different isoforms with 121, 165, 189 and 206 amino acids (VEGF 121 , VEGF 165 , VEGF 189 , VEGF 206 , respectively). In 2002, a sister family of VEGF-A isoforms termed VEGF xxx b was identified (Bates et al., 2002; Ladomery et al., 2007) . VEGF xxx b isoforms are generated by the use of an alternative 3 0 splice acceptor site in the final exon 8 of VEGF-A, leading to the synthesis of proteins of the same length, but with distinct C-terminal six amino acids (Bates et al., 2002) . At the biological level, VEGF xxx isoforms are pro-angiogenic and are upregulated in human tumours, whereas VEGF xxx b isoforms are antiangiogenic and are downregulated in some tumours (Bates et al., 2002; Woolard et al., 2004; Pritchard-Jones et al., 2007) . It has been shown that VEGF 165 b binds VEGFR-2 and inhibits its downstream classical signalling pathway (Woolard et al., 2004; Kawamura et al., 2008) . Moreover, VEGF 165 b overexpression inhibits the growth of prostate carcinoma, Ewing's sarcoma and renal cell carcinoma in xenograft mouse tumour models through the inhibition of tumour-cell-mediated migration and proliferation of endothelial cells . Furthermore, VEGF 165 b binds and inhibits Bevacizumab (Avastin), a humanized monoclonal antibody directed against VEGF-A that is currently used in clinics (Varey et al., 2008) . As a whole, these data indicate that the balance between pro-(VEGF xxx ) and anti-(VEGF xxx b) angiogenic splice variants of VEGF-A has a critical role in both tumour progression and tumour cell response to antiangiogenic therapies. However, although there has been some investigation of splicing mechanisms in epithelial cells (Cohen et al., 2005; Nowak et al., 2008 Nowak et al., , 2010 , little is known about the proteins and signalling networks that control the splicing of VEGF-A pre-mRNA in cancer cells.
The transcription factor E2F1 belongs to the E2F family, which comprises eight members. Initially, studies revealed that E2F1 determines the timely expression of many genes required for S-phase entry and progression. However, it has become clear that transcriptional activation of the S-phase-related genes is only one facet of E2F1 activity. Indeed, E2F1 functions in a wide range of biological processes, including DNA replication, mitosis, DNA repair, cell differentiation and apoptosis (Polager and Ginsberg, 2008) . In addition, E2F1 downregulates the activity of the VEGF promoter under hypoxic conditions through a p53-dependent mechanism, unravelling an unexpected function of E2F1 in the control of angiogenesis (Qin et al., 2006) . Recently, we established the first link between E2F1-and pre-mRNAprocessing events by identifying SC35, a member of the SR (Ser-Rich/Arg) family of proteins that is involved in constitutive and alternative pre-mRNA splicing, as a direct transcriptional target of E2F1 (Merdzhanova et al., 2008) . On the basis of these results, we questioned whether E2F1 and/or SC35 proteins could control VEGF-A expression and/or pre-mRNA splicing in p53-deficient tumour cells.
Results

E2F1 downregulates the expression of pro-angiogenic VEGF xxx isoforms independently of p53
In a murine system, it was previously shown that E2F1 decreases the level of VEGF in a p53-dependent manner (Qin et al., 2006) . To test whether E2F1 could also control VEGF expression in human tumour cells deficient in p53, we took advantage of previously established stable E2F1-inducible clones in the H358 cell line derived from a human lung adenocarcinoma. In this system, E2F1 or an E2F1(E132) DNA-binding defective mutant is overexpressed upon doxycycline treatment (Figure 1a, upper panel) . As detected by reverse transcription-polymerase chain reaction (RT-PCR) analysis, we observed a significant decrease in VEGF 189 , VEGF 165 and VEGF 121 mRNA levels in cells overexpressing E2F1 (Figure 1a , middle panel). The DNA-binding activity of E2F1 was required in this setting, as a similar decrease was not observed when the E2F1 mutant (E132) was overexpressed. Importantly, we also observed a decrease in both VEGF 165 and VEGF 189 mRNA levels in E2F1-overexpressing cells when we performed RT-PCR analysis using primers targeting exons 7 and 8a of VEGF-A that do not detect VEGF xxx b isoforms (Bates et al., 2006; Pritchard-Jones et al., 2007; Varey et al., 2008) (Figure 1a, lower panel) . Therefore, these data indicate that E2F1 downregulates the expression level of pro-angiogenic VEGF xxx transcripts. To test whether this effect was specific for VEGF xxx transcripts, we analysed the expression level of neuropilin-1, the co-receptor of VEGFR-2 that was recently identified as a new E2F1 transcriptional target gene (Jiang et al., 2007) . Upon E2F1 overexpression, we found that the level of neuropilin-1 mRNA was slightly increased, whereas the expression of neuropilin-2 was not affected (Figure 1a , lower panel). These data indicate that E2F1 specifically decreases the expression of VEGF xxx mRNAs. To confirm these results, we performed quantitative RT-PCR (RT-qPCR) experiments using primers detecting either all or each VEGF isoform (Table 1) (Catena et al., 2007) . We found that VEGF 121 , VEGF 165 and VEGF 189 mRNA levels significantly decreased upon E2F1 induction, whereas this was not the case with the mutant E2F1(E132) (Figure 1b) . To extend these results at the protein level, we quantified the expression of VEGF in supernatants or in total cellular extracts from E2F1-or E2F1(E132)-overexpressing cells using enzyme-linked immunosorbent assay (ELISA) or western blotting, respectively. We observed that wild-type E2F1 significantly decreased VEGF levels in both the culture medium ( Figure 1c ) and the cell extracts (Figure 1d ), as compared with mutant E2F1(E132), which did not have any effects. To confirm these results, we knocked down E2F1 by using a pool of two distinct small interfering RNAs (siRNAs) in the H69 cell line that expresses high levels of E2F1 and is deficient in p53. In these cells, the silencing of E2F1 (Figure 2a , left panel) was accompanied by a significant increase of VEGF 121 , VEGF 165 and VEGF 189 mRNA levels as detected by right panel) . These data were confirmed by ELISA assay and western blotting. Indeed, we found that neutralization of E2F1 increased VEGF levels in both culture supernatants ( Figure 2b ) and cellular extracts (Figure 2c) . Overall, these data show that E2F1 negatively controls VEGF xxx mRNA and protein levels in tumour cells independently of p53 and under normoxic conditions. E2F1 inhibits VEGF-A promoter activity in a p53-independent manner On the basis of our data showing that E2F1 affects the expression of VEGF xxx isoforms independently of p53, we next questioned whether E2F1 could act by controlling the activity of the VEGF-A promoter. H1299 cells were transiently co-transfected with a 2.4-kb VEGF promoter-luciferase construct (pVp-ecor; Figure 3a ; Zhang et al., 2000) and increasing amounts of plasmid encoding E2F1, and the luciferase activity was measured 48 h later. As shown in Figure 3b (left panel), E2F1 strongly inhibited the activity of the VEGF promoter in a dose-dependent manner, whereas it did not affect the activity of the control pGL3-luc vector. Similar results were obtained in SAOS2 cells (Figure 3b , right panel). This effect of E2F1 on the Vegf promoter was direct. Indeed, by performing chromatin immunoprecipitation experiments in H358/Tet-On/E2F1 cells cultured in the presence or absence of doxycycline, we further provided evidence that E2F1 binds to the Vegf promoter, whereas no binding to the glyceraldehyde-3-phosphate dehydrogenase (Gapdh) promoter was observed (Supplementary Figure S1) . To confirm the effects of E2F1, we analysed the consequences of its knockdown on the activity of the VEGF promoter in cells that were co-transfected with either pVp-ecor or pGL3-luc and siRNAs targeting E2F1. In both cellular models, the neutralization of E2F1 significantly increased the activity of the VEGF promoter, as compared with cells that were transfected with mismatch siRNA. E2F1 had no effect on the pGL3-luc promoter activity (Figure 3c ). Taken together, these results show that E2F1 can repress VEGF-A promoter activity independently of p53 and under normoxic conditions. (Bates et al., 2002 (Bates et al., , 2006 Woolard et al., 2004; Pritchard-Jones et al., 2007; Rennel et al., 2008) . Using primers that were complementary to exons 4 and 8b, we were able to amplify a fragment with a size that was consistent with the VEGF 165 b transcript ( Figure 4b , right panel). We observed that expression of the VEGF 165 b transcript increased in response to E2F1 induction, a phenomenon that was not observed with the E2F1 mutant (E132). Similar results were obtained using another set of primers that was complementary to exons 7 and 7/8b, and that allowed the detection of VEGF 165 b mRNA only ( Figure 4b ) (Pritchard-Jones et al., 2007) . Therefore, although E2F1 decreases VEGF xxx mRNA and protein levels, it seems to affect the expression of VEGF xxx b isoforms in an opposite manner. To confirm these results, we designed primers to perform isoform-specific qPCR of VEGF 121 b, VEGF 165 b and VEGF 189 b splice variants (Table 1 and Figure 4a ). Using these specific sets of primers, we showed in our model that E2F1 . As a dominant-negative effect of E2F1(E132) has been reported previously (Davis et al., 2006) , these results suggest that the binding of E2F1 to DNA is required for the expression of VEGF xxx b splice variants. To confirm these results at the protein level, we performed western blot experiments using an anti-VEGF xxx b antibody (Woolard et al., 2004) . The results showed that in H358 cells, the level of VEGF 165 b protein increased when the expression of E2F1 was induced by doxycycline treatment ( Figure 4d , left panel). In these cells, we were not able to detect the VEGF 121 b protein. By contrast, the knockdown of E2F1 in H69 cells correlated with a significant decrease in both VEGF 165 b and The splicing factor SC35 is required for E2F1-induced VEGF 165 b upregulation We recently identified the splicing factor SC35, a member of the SR family of proteins, as a direct transcriptional target of E2F1 (Merdzhanova et al., 2008) . These data led us to postulate that SC35 could be involved in the control of the VEGF xxx b/VEGF ratio by E2F1. To test this hypothesis, two distinct siRNAs targeting sc35 were transfected into H358/Tet-On/E2F1 cells cultured in the presence or absence of doxycycline, and the expression of VEGF xxx and VEGF 165 b splice variants was analysed by RT-PCR ( Figure 5a ) and western blotting (Figure 5b ). In both experiments, the knockdown of SC35 strongly prevented the E2F1-induced increase of VEGF 165 b (Figures 5a and b) . Notably, we observed that the neutralization of SC35
per se decreased the level of VEGF xxx mRNA, whereas it did not significantly affect the levels of VEGF 165 b mRNA. To mimic the induction of SC35 that is detected in E2F1-overexpressing cells, we established inducible SC35 clones derived from H358/Tet-On cells. As shown in Figure 5c , induction of SC35 expression by doxycycline strongly increased the VEGF 165 b/VEGF ratio, indicating that SC35 accumulation recapitulates E2F1 overexpression. Taken together, these results show that SC35 is required for E2F1-mediated VEGF 165 b upregulation in H358 human lung carcinoma cells and suggest that both E2F1 and SC35 proteins cooperate to favour the expression of VEGF xxx b isoforms.
E2F1 and SC35 inhibit neovascularization in vivo by modulating the VEGF xxx b/VEGF ratio As we showed that E2F1 affects the VEGF xxx b/VEGF ratio in vitro, we wondered whether this effect could be observed in vivo. H358/Tet-On 4 (Tet-On 4; control cells) and H358/Tet-On/E2F1-6 (E2F1-6) cells were subcutaneously injected into immunodeficient nude mice, and the induction of E2F1 expression was achieved by adding doxycycline (Dox þ ) to the drinking water. To eliminate the potential effects of E2F1 E2F1 controls VEGF-A alternative splicing G Merdzhanova et al induction on apoptosis and to focus our analysis on early events such as neoangiogenesis, the mice were killed 7 days after drinking doxycycline. Tumours were weighed, and total proteins were extracted from whole tumoural samples. We observed that the induction of E2F1 (E2F1-6, Dox þ ) significantly diminished the weight of the tumours (P ¼ 0.0362), a phenomenon that was not observed in the Tet-On 4 control tumours receiving doxycycline (Tet-On 4, Dox þ ; Figure 6a ). We also noted that tumours overexpressing E2F1 (E2F1-6, Dox þ ) were less haemorrhagic than those derived from control cells (Tet-On 4, Dox þ ), as well as those from E2F1-6 cells in which the expression of E2F1 was not induced (E2F1-6, DoxÀ) ( Figure 6b , upper panel). Consistent with these findings, the haemoglobin levels were significantly decreased on E2F1 induction (E2F1-6, Dox þ ), as compared with uninduced E2F1-6 tumours (E2F1-6, DoxÀ) ( Figure 6b , lower panel; P ¼ 0.007). This effect was specific as doxycycline did not affect haemoglobin levels in tumours derived from Tet-On 4 control cells. Such an inhibitory effect of E2F1 on tumour neovascularization was further confirmed using CD31 immunostaining of murine endothelial cells. As shown in Figure 6c (upper and lower panels), tumours overexpressing E2F1 displayed significantly less infiltrating murine vessels, as compared with all other conditions (P ¼ 0.0044). In addition, murine stroma surrounding tumours also appeared less vascularized in E2F1-overexpressing tumours as compared with all other conditions (data not shown). Altogether, these results show that E2F1 prevents neovascularization. To analyse whether this could be linked to modifications of Figure S2 ) as compared with uninduced tumours. Notably, pan-VEGF protein levels were not significantly affected in tumours overexpressing SC35. Taken together, these results show that E2F1 and SC35 proteins can modulate the ratio between the pro-and antiangiogenic isoforms of VEGF in favour of the antiangiogenic entities in vivo, leading to the inhibition of tumour neovascularization.
Discussion
E2F1 was first identified as a crucial regulator of cell cycle progression. However, based on the growing number of studies published in the past decade, it is now clear that E2F1 has numerous other biological roles. Recently, a new function for E2F1 as a negative regulator of angiogenesis has been proposed based on the revelation that mice deficient in E2F1 exhibit enhanced angiogenesis as a result of VEGF overproduction (Qin et al., 2006) . In this model, increased angiogenesis occurs during both recovery from ischaemic injury and tumour growth and is dependent on wildtype p53. In this study, we show that E2F1 negatively affects the activity of the VEGF-A promoter in p53-deficient tumour cell lines and under normoxic conditions, indicating that neither hypoxia nor p53 are required for E2F1-mediated VEGF repression in cancer cells. Interestingly, during the writing of this paper, it was also shown that E2F1 cooperates with mutant p53-R175H to promote angiogenesis through the induction of pro-angiogenic soluble mediators (Fontemaggi et al., 2009) . Therefore, these data along with our findings suggest that E2F1 could control angiogenesis in an opposite way depending on the status of p53. An increasing amount of evidence now supports the idea that the balance between VEGF xxx (pro-angiogenic) and VEGF xxx b (antiangiogenic) splice variants has a crucial role in the control of tumour progression, as well as in the response of tumour cells to anti-VEGF therapies (Bates et al., 2002; Woolard et al., 2004; Rennel et al., 2008; Varey et al., 2008) . Recently, it has been shown that VEGF splicing is controlled by the SR proteins ASF/SF2, SRp40 and SRp55 in primary epithelial cells (Nowak et al., 2008 (Nowak et al., , 2010 . To date, nothing is known about the factors that control the switch between VEGF xxx and VEGF xxx b splice variants in cancer cells. In this study, we provide evidence that E2F1 controls the angiogenic switch between pro-and antiangiogenic isoforms of VEGF and favours the expression of the antiangiogenic forms in human lung carcinoma cell lines. What could be the molecular mechanisms involved in this process? We provide evidence that E2F1 decreases the activity of the VEGF-A promoter. Therefore, one possibility is that E2F1 could specifically affect the transcription of pro-angiogenic isoforms, but not that of antiangiogenic isoforms because of the use of a different region of the promoter. Another possibility is that E2F1 downregulates the transcription of both pro-and antiangiogenic VEGF isoforms, but favours the use of the distal splice site within exon 8 of the pre-mRNA, thereby generating more antiangiogenic isoforms. In favour of such a hypothesis, we provide evidence that the SR protein SC35 is absolutely required for VEGF 165 b accumulation in response to E2F1, and we show that overexpression of SC35 mimics the positive effects of E2F1 on VEGF 165 b and also decreases the total amount of VEGF. Of note, SC35 did not downregulate the activity of the VEGF-A promoter in our cellular models (data not shown). Therefore, these data strongly suggest that the positive effects of E2F1 on the VEGF xxx b/ VEGF balance mainly reflect a splicing event through SC35 upregulation and the preferential choice of the distal splice site inside the VEGF-A pre-mRNA. However, the role of SC35 might vary depending on its global amount as its knockdown in H358 cells (Figure 5a ), and in other carcinoma cell lines (data not shown), it was found to decrease rather than increase the amount of VEGF. Interestingly, we also observed that E2F1 strongly increases VEGF 165 b and VEGF 189 b mRNA levels in H358/Tet-On/E2F1 cells, without affecting the levels of VEGF 121 b. Therefore, besides its effects on splicing, we cannot exclude that E2F1 also regulates VEGF xxx b mRNA stability. Of note, this effect could be dependent on the cell type, as the level of VEGF 121 b protein strongly decreased in H69 cells deprived of E2F1 (Figure 4d ). Overall, these results suggest another level of complexity in the regulation of VEGF-A splicing by E2F1 and SR proteins in human cancer cells that could be dependent on the cell type, the upstream signals and the total amount of various SR proteins. Finally, using lung xenografts in nude mice, we show that the inhibition of tumour growth by E2F1 correlates with a decrease in tumour neovascularization, as well as a significant increase of the VEGF 165 b/VEGF balance in vivo. Moreover, we provide evidence that tumours overexpressing SC35 also express a greater quantity of VEGF 165 b protein and a lower level of neo-vasculature, as compared with control tumours. Recently, it was shown that overexpressing VEGF 165 b reduces the growth of renal carcinoma cell xenografts, even in the presence of VEGF 165 . These data, along with our findings, strongly suggest that the positive effects of E2F1 and SC35 proteins on VEGF 165 b are involved in the reduction of tumour neovascularization. E2F1-deficient mice exhibit impaired apoptotic function, which was previously presumed to explain the increased incidence of cancer in these mice. The results presented herein strongly suggest that this could also result from an increase in the vascular supply of tumours secondary to dysregulated VEGF pre-mRNA splicing. Therefore, besides its ability to control the alternative splicing of apoptotic regulators during apoptosis (Merdzhanova et al., 2008) , E2F1 also has the capacity to regulate VEGF-A pre-mRNA alternative splicing to modulate neo-angiogenesis. These data add further evidence that the regulation of pre-mRNA processing events is a key function of E2F1 that could contribute to its seemingly contradictory roles as both an oncogene and a tumour suppressor.
Materials and methods
Cell lines, plasmids, transfection and luciferase assays H358, H1299, H69 and SAOS2 cell lines were cultured as described previously (Salon et al., 2007) . All of these cell lines are defective for wild-type p53. The human lung adenocarcinoma H358/Tet-On/E2F1, Tet-On/E2F1(E132) and Tet-On/ SC35 inducible clones were obtained as described previously (Salon et al., 2006) . E2F1, E2F1(E132) or SC35 expression was induced with 1 mg/ml doxycyline treatment. Transient transfections were carried out using Fugene 6 (Roche Diagnostic, Meylan, France). The plasmids used in transient transfections were pcDNA3, pCMV-E2F1, pGL3-promoter vector and pVp-ecor encoding luciferase under the control of the whole human VEGF promoter (À2362 to þ 956 relative to the transcriptional start site (Zhang et al., 2000) ). Luciferase assays were performed as described previously (Salon et al., 2007) .
Enzyme-linked immunosorbent assay
For the quantitative determination of human VEGF concentrations in cell culture supernatants, 3 Â 10 5 cells were seeded into six-well plates and incubated for 24 or 48 h before the supernatants were recovered. The determination of VEGF concentrations was performed by ELISA using the Quantikine VEGF immunoassay (DVE00) from R&D Systems (Lille, France). Of note, this assay has been shown to measure all VEGF isoforms, although VEGF 165 b is detected at a lower efficiency according to Varey et al. (2008) .
Antibodies and immunoblotting experiments
Antibodies used were anti-panVEGF (MAB293) and anti-VEGF 165 b (MAB3045) from R&D Systems; anti-panVEGF (A-20), anti-E2F1 (C-20) and anti-actin from Santa Cruz (TEBU-Bio SA, Le Perray en Yvelines, France); anti-E2F1 (KH95) and anti-mouse CD31 from BD Biosciences (Le Pont de Claix, France); and anti-SC35 (4F11) from Euromedex (Souffelweyersheim, France). Immunoblotting experiments were performed as described previously (Salon et al., 2006) .
Transfection of siRNA oligonucleotides
The sequences designed to specifically target human e2f1 RNA were as follows: (1) 5 0 -GUCACGCUAUGAGACCUCATT-3 0 ; T-3 0 . The sequences designed to specifically target human sc35 RNAs were as follows: sc35 (1) 5 0 -GCGUCUUCGAGAAGUA CGGTT-3 0 ; sc35 (2) 5 0 -UCGUUCGCUUUCACGACAATT-3 0 . The scrambled siRNA oligonucleotides used as a control for all RNA interference experiments were as follows: 5 0 -UCGG CUCUUACGCAUUCAATT-3 0 and 5 0 -CAAGAAAGGCCA GUCCAAGTT-3 0 . Cells were transfected with siRNA oligonucleotide duplexes using Oligofectamine reagent (Invitrogen, Cergy Pontoise, France). Doxycycline (1 mg/ml) was or was not added to the culture medium 4 h after transfection. The cells were analysed 48 or 72 h post-transfection.
RT-PCR and RT-qPCR analyses
All of the primers that were used for the detection of VEGF xxx , VEGF xxx b, neuropilin-1 and neuropilin-2 mRNAs by RT-PCR (Cheung et al., 1998; Lantuejoul et Table 1 . For RT-PCR analysis, total cellular RNAs were isolated using Trizol reagent (Invitrogen). In all conditions, 1 mg of total RNA was reversed transcribed using oligo(dT) primers and Moloney murine leukaemia virus reverse transcriptase (Invitrogen). For the detection of neuropilin-1, the PCR conditions were 94 1C for 2 min, 34 cycles of 94 1C for 45 s, 60 1C for 1 min and 72 1C for 1 min, and 72 1C for 10 min. For the detection of neuropilin-2, the PCR conditions were 95 1C for 2 min followed by 39 cycles of 94 1C for 15 s, 50 1C for 30 s and 72 1C for 30 s, and 72 1C for 7 min. For VEGF xxx amplification, the PCR conditions (Cheung et al., 1998) were as follows: 94 1C for 2 min, 29 cycles of 94 1C for 45 s, 60 1C for 1 min and 72 1C for 1 min, and 72 1C for 10 min. The detection of VEGF xxx transcripts using an exon 7 forward primer and a reverse-specific primer for exon 8a that do not detect VEGF xxx b transcripts was performed as described previously (Pritchard-Jones et al., 2007) . To detect the antiangiogenic VEGF xxx b splice variants, the PCR conditions were 94 1C for 2 min, 35 cycles of 96 1C for 30 s, 65 1C for 30 s, 72 1C for 1 min, and 72 1C for 10 min for the exon 4/exon 8b primer set. For the exon 7a/exon 8b primer set, the PCR conditions were 96 1C for 30 s, 35 cycles of 55 1C for 30 s, 72 1C for 1 min, and 72 1C for 10 min. Amplification of a GAPDH cDNA (Invitrogen) fragment was performed in the same PCR reaction as an internal control. PCR products were run in a 2-3% agarose gel and were visualized by ethidium bromide staining.
Quantitative real-time RT-PCR was performed on the Stratagene MX3005P apparatus. In total, 1 mg of total RNA was subjected to cDNA synthesis using the Superscript III First-Strand Synthesis SuperMix for qPCR (Invitrogen) and was subsequently amplified during 40 PCR cycles (10 min at 95 1C and cycles of 15 s at 95 1C and 1 min at 60 1C) using Power SYBR Green PCR Master Mix (Applied Biosystems, Courtaboeuf, France). In parallel, RT-PCR detection of the reference gene GAPDH was performed for each sample. Relative gene expression was calculated for each sample, as the ratio of target gene copy number to GAPDH mRNA copy number multiplied by 100; thus, normalizing the expression of VEGF xxx and VEGF xxx b splice variants. The PCR efficiency was assessed for each set of primers and ranged from 106 to 110%.
In vivo studies All animal experiments were conducted in agreement with the 'Principles of Laboratory Animal Care' (NIH publication no. 86-23, revised 1985) and were approved by a regional ethics committee. Female athymic Swiss nude mice were purchased from Janvier (Le Genest-Isle, France). In all experiments, 20 Â 10 6 H358/Tet-On/E2F1, H358/Tet-On/SC35 or H358/ Tet-On 4 cells were injected subcutaneously into the nude mice. One week after injection, the mice were randomly separated into two groups (seven mice per group), one receiving doxycycline (2 mg/ml) in their drinking water and the other receiving water only. Seven days later, mice were anaesthetized and killed by cervical dislocation, and the tumours were extracted, weighed and divided before freezing. For western blot analysis, tumours were homogenized in radio immunoprecipitation assay buffer containing protease and phosphatase inhibitors, and immunoblotting was performed on the supernatants as above. The extent of vascularization in tumour samples was assessed in radio immunoprecipitation assay extracts by measuring the amount of haemoglobin using Drabkin's reagent (Sigma, Lyon, France). The results were normalized relative to the amount of protein in each sample. For CD31 immunodetection, frozen sections were fixed in 3.7% paraformaldehyde and immunostained with a rat antimouse CD31 (platelet/endothelial cell adhesion molecule-1) antibody using a three-step indirect immunoperoxidase technique.
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